SS-31 (Elamipretide): A Research Overview

SS-31 is one of the more rigorously studied compounds in this library — a mitochondria-targeting peptide that has been through a substantial program of human clinical trials under the drug name elamipretide. Its mechanism is well-defined, and its clinical record is real, which means the honest task here is twofold: convey the genuine science and trial history accurately, and also be candid that the trial results have been mixed across indications. In September 2025, elamipretide received FDA accelerated approval — as FORZINITY — for the narrow indication of improving muscle strength in Barth syndrome, but it remains investigational (and has had mixed results) for the other conditions it has been studied in. This is a serious drug-development story with one hard-won, narrow approval, not a broadly settled therapy.

This overview summarizes what the published literature and trial record report about SS-31 — its structure, mechanism, evidence, status, and safety. It describes findings as they appeared in their study systems. It is not dosing guidance, medical advice, or a recommendation for use.

What SS-31 Is

SS-31 is a synthetic mitochondria-targeting tetrapeptide, developed clinically as elamipretide (also known as MTP-131 and Bendavia). It belongs to a class of small cell-permeable peptides with alternating cationic-aromatic motifs that was discovered serendipitously during work on opioid-receptor peptides, though elamipretide itself has little to no opioid activity (elamipretide origin and class). Despite a strong positive charge, it crosses the plasma membrane and accumulates strongly at the inner mitochondrial membrane.

Mechanism — Targeting Cardiolipin

SS-31’s defining action is selective binding to cardiolipin, a signature lipid of the inner mitochondrial membrane. By associating with cardiolipin, SS-31 helps stabilize the membrane’s folded cristae structure, supports the proper assembly of cardiolipin-dependent proteins of the electron transport chain, reduces excess oxidative stress (reactive oxygen species), and improves ATP production (cardiolipin-binding mechanism). In essence, it is studied as a way to restore the structure and energy output of dysfunctional mitochondria — a “membrane-level” mitochondrial support, mechanistically distinct from signaling peptides like MOTS-c.

The Evidence Base — Extensive but Mixed

SS-31 has an unusually deep evidence base for this library: protective effects across many preclinical models (heart failure, ischemia-reperfusion, kidney injury, neurodegeneration, muscle atrophy, the genetic disorder Barth syndrome), and a genuine human clinical program — trials including MMPOWER-3 (primary mitochondrial myopathy), TAZPOWER (Barth syndrome), ReCLAIM (age-related macular degeneration), and cardiovascular studies (clinical-trial program summary). Reviews have systematically analyzed many human trials of SS-31 (systematic analysis of human trials). The crucial honesty point: the results have been mixed — some trials and endpoints showed benefit, while others did not meet their primary endpoints. On the strength of the Barth syndrome data (the TAZPOWER knee extensor strength endpoint), elamipretide received FDA accelerated approval as FORZINITY in September 2025 for Barth syndrome specifically (FDA accelerated approval (FORZINITY, Sept 2025)); it is the first FDA-approved mitochondria-targeted therapeutic. Outside that narrow indication, it remains investigational, and as an accelerated approval, continued approval may depend on confirmatory trials. Strong, sustained development and a genuinely promising mechanism — with one narrow approval rather than broad, finished success.

• Mitochondria-targeting tetrapeptide; binds cardiolipin to stabilize cristae and improve bioenergetics.
• Deep preclinical record plus multiple completed human trials (Barth syndrome, mitochondrial myopathy, AMD, heart failure).
• Trial results are mixed across indications; FDA accelerated approval as FORZINITY for Barth syndrome (Sept 2025); still investigational for other uses.

Safety Considerations

Across its clinical trials, elamipretide has generally been reported as well-tolerated, with injection-site reactions among the more common effects observed. Its complete long-term safety profile is still being characterized through ongoing trials and, for Barth syndrome, a post-approval confirmatory study. As always, research-grade SS-31 is distinct from the clinical-trial drug elamipretide and carries the usual purity and handling uncertainties of unregulated peptides; well-tolerated in supervised trials does not equate to safe for unsupervised use.

Regulatory Status

The status below reflects mid-2026 and may change; verify before relying on it. In September 2025, elamipretide received FDA accelerated approval under the brand name FORZINITY to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg — the first FDA-approved treatment for Barth syndrome and the first approved mitochondria-targeted therapeutic. Because this is an accelerated approval, continued approval may be contingent on confirmatory trials. For its other studied indications (primary mitochondrial myopathy, age-related macular degeneration, heart failure), elamipretide remains investigational. Critically, research-grade material sold as “SS-31” is not FORZINITY or any approved drug; it is sold for laboratory use only and is, by its labeling, not for human consumption.

Why SS-31 Draws Research Interest

SS-31 is a leading example of mitochondria-targeted therapeutics — a mechanistically well-defined, cardiolipin-binding peptide with one of the most developed clinical programs among the compounds in this library. The accurate framing is a serious mitochondrial drug with a strong mechanism and extensive trials, mixed clinical results across indications, a narrow 2025 FDA accelerated approval (FORZINITY) for Barth syndrome, continued investigational status elsewhere, and a research-grade form distinct from the approved drug.

For deeper reading, the cited literature is the best starting point. SS-31 is mechanistically complementary to the signaling mitochondrial peptide MOTS-c and connects to broader cellular energy research, such as NAD+. The wider class is collected in our peptide research library.